Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Vir Biotechnology Inc. Common Stock trades at $10.5 (market cap $1.76B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 5× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is more actively traded (2,764,948 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| KYMR | VIR | |
|---|---|---|
Market Cap | $8.88B | $1.76B |
Volume | 1,028,790 | 2,764,948 |
Sector | Health | Health |
52-Week High | $127.31 | $11.78 |
52-Week Low | $55.80 | $5.12 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $8.27B | $1.32B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Vir Biotechnology Inc. Common Stock
Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →
